{"id":334951,"date":"2026-11-12T07:08:00","date_gmt":"2026-11-12T06:08:00","guid":{"rendered":"https:\/\/geneveinfos.ch\/?p=334951"},"modified":"2026-11-12T23:10:29","modified_gmt":"2026-11-12T22:10:29","slug":"neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars","status":"publish","type":"post","link":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/","title":{"rendered":"Neurosterix: Geneva biotech raises 105 million dollars"},"content":{"rendered":"<p class=\"gi-temps\">\u23f1 2 min read<\/p>\n<h3>Background<\/h3>\n<p>Neurosterix is a Geneva-based biotechnology company created in April 2024 by Addex Therapeutics. It develops treatments for neuropsychiatric disorders. At its launch, it raised 65 million dollars in a Series A led by funds affiliated with Perceptive Advisors. Its lead candidate, NTX-253, targets schizophrenia.<\/p>\n<h3>The key points<\/h3>\n<p>On Wednesday 11 November 2026, Addex Therapeutics announced that <strong>Neurosterix<\/strong> had closed a Series B financing of <strong>105 million dollars<\/strong>. The investors are described as a syndicate of life science investors, without being named, according to Fierce Biotech. Addex did not take part in this round.<\/p>\n<p>The priority is the phase 2 trial of <strong>NTX-253<\/strong> in schizophrenia. This oral drug acts on the brain\u2019s M4 muscarinic receptors. It aims to reduce psychotic symptoms while avoiding some side effects of conventional treatments. Phase 1 studies are complete. The remaining funds will go to two other molecules, NTX-819 for mood and anxiety, and NTX-529.<\/p>\n<p>The company also announced the arrival of executives specialised in neuropsychiatric drug development. Its CEO is Fred Callori, also a managing director at Perceptive Advisors.<\/p>\n<h3>Key figures<\/h3>\n<ul>\n<li><strong>105 million dollars<\/strong> : size of the Series B, announced on 11 November 2026<\/li>\n<li><strong>65 million dollars<\/strong> : Series A raised in April 2024<\/li>\n<li><strong>8,5 %<\/strong> : Addex\u2019s stake in Neurosterix, down from 20% in 2024<\/li>\n<\/ul>\n<h3>Who says what<\/h3>\n<ul>\n<li><strong>Tim Dyer<\/strong> (CEO of Addex Therapeutics): this financing endorses the allosteric approach developed by Addex.<\/li>\n<\/ul>\n<h3>What's next<\/h3>\n<ul>\n<li>Launch of the <strong>phase 2<\/strong> trial of NTX-253 in schizophrenia; no date has been given.<\/li>\n<\/ul>\n<h3>Further reading<\/h3>\n<ul class=\"gi-related\">\n<li><a href=\"https:\/\/geneveinfos.ch\/en\/2026\/08\/31\/addex-therapeutics-extends-its-cash-runway-into-the-fourth-quarter-of-2027\/\">Addex Therapeutics: cash runway extended to end-2027<\/a><\/li>\n<li><a href=\"https:\/\/geneveinfos.ch\/en\/2026\/11\/10\/bioscibex-in-monthey-innosuisse-supports-a-million-euro-project\/\">Bioscibex in Monthey: Innosuisse backs a CHF 1 million project<\/a><\/li>\n<\/ul>\n<h3>Sources<\/h3>\n<ul class=\"gi-sources\">\n<li><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/addex-spinout-neurosterix-raises-105m-series-b-fund-phase-2-schizophrenia-trial\" target=\"_blank\" rel=\"noopener nofollow\">Fierce Biotech \u2013 Addex spinout Neurosterix raises $105M series B to fund phase 2 schizophrenia trial<\/a><\/li>\n<li><a href=\"https:\/\/neurosterix.com\/investors-media\/\" target=\"_blank\" rel=\"noopener nofollow\">Neurosterix \u2013 Investors &amp; Media<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>On Wednesday 11 November 2026, Addex Therapeutics announced that Neurosterix had closed a 105 million dollar Series B financing.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[128,102],"tags":[127,133],"class_list":["post-334951","post","type-post","status-publish","format-standard","hentry","category-actu-suisse-romande","category-pharma-biotech","tag-fiche-bilingue","tag-lieu-geneve"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.5.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Neurosterix, biotech genevoise issue d\u2019Addex, l\u00e8ve 105 millions de dollars en s\u00e9rie B pour l\u2019essai de phase 2 du NTX-253 contre la schizophr\u00e9nie.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Morgane Ravouna\"\/>\n\t<meta name=\"msvalidate.01\" content=\"F6FB81358B9B97D1D2B21C8A22A9AB69\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.5.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_GB\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Gen\u00e8ve Infos - L\u2019actu genevoise et romande\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars\" \/>\n\t\t<meta property=\"og:description\" content=\"Neurosterix, biotech genevoise issue d\u2019Addex, l\u00e8ve 105 millions de dollars en s\u00e9rie B pour l\u2019essai de phase 2 du NTX-253 contre la schizophr\u00e9nie.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/geneveinfos.ch\/wp-content\/uploads\/2026\/11\/geneveinfos-partage-2026-en.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/geneveinfos.ch\/wp-content\/uploads\/2026\/11\/geneveinfos-partage-2026-en.jpg\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-11-12T06:08:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-11-12T22:10:29+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61576016541234\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Neurosterix, biotech genevoise issue d\u2019Addex, l\u00e8ve 105 millions de dollars en s\u00e9rie B pour l\u2019essai de phase 2 du NTX-253 contre la schizophr\u00e9nie.\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/geneveinfos.ch\/wp-content\/uploads\/2026\/11\/geneveinfos-partage-2026-en.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/category\\\/pharma-biotech\\\/#listItem\",\"name\":\"Pharma &amp; biotech\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/category\\\/pharma-biotech\\\/#listItem\",\"position\":2,\"name\":\"Pharma &amp; biotech\",\"item\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/category\\\/pharma-biotech\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#listItem\",\"name\":\"Neurosterix : la biotech genevoise l\\u00e8ve 105 millions de dollars\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#listItem\",\"position\":3,\"name\":\"Neurosterix : la biotech genevoise l\\u00e8ve 105 millions de dollars\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/category\\\/pharma-biotech\\\/#listItem\",\"name\":\"Pharma &amp; biotech\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#newsarticle\",\"name\":\"Neurosterix : la biotech genevoise l\\u00e8ve 105 millions de dollars\",\"headline\":\"Neurosterix : la biotech genevoise l\\u00e8ve 105 millions de dollars\",\"author\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/author\\\/redaction-geneve-infos\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/geneveinfos.ch\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/logo-geneveinfos-fr.png\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/#articleImage\",\"width\":920,\"height\":958,\"caption\":\"Gen\\u00e8ve Infos \\u2013 logo\"},\"datePublished\":\"2026-11-12T07:08:00+01:00\",\"dateModified\":\"2026-11-12T23:10:29+01:00\",\"inLanguage\":\"en-GB\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#webpage\"},\"articleSection\":\"Actus, Pharma &amp; biotech, Fiche bilingue, Gen\\u00e8ve\",\"dateline\":\"Published on November 12, 2026.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/#organization\",\"name\":\"Gen\\u00e8ve Infos\",\"description\":\"M\\u00e9dia \\u00e9conomique de Gen\\u00e8ve et de toute la Suisse romande. Actus, articles et agenda, de Gen\\u00e8ve au Jura.\",\"url\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/geneveinfos.ch\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/logo-geneveinfos-fr.png\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#organizationLogo\",\"width\":920,\"height\":958,\"caption\":\"Gen\\u00e8ve Infos \\u2013 logo\"},\"image\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61576016541234\",\"https:\\\/\\\/www.instagram.com\\\/geneveinfos.ch\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/geneveinfos-ch\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/author\\\/redaction-geneve-infos\\\/#author\",\"url\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/author\\\/redaction-geneve-infos\\\/\",\"name\":\"Morgane Ravouna\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a611ac9406717aef02499144d0e12a8f5e1327b66a2e6023de2c094c4937e1d?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Morgane Ravouna\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#webpage\",\"url\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/\",\"name\":\"Neurosterix : la biotech genevoise l\\u00e8ve 105 millions de dollars\",\"description\":\"Neurosterix, biotech genevoise issue d\\u2019Addex, l\\u00e8ve 105 millions de dollars en s\\u00e9rie B pour l\\u2019essai de phase 2 du NTX-253 contre la schizophr\\u00e9nie.\",\"inLanguage\":\"en-GB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/2026\\\/11\\\/12\\\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/author\\\/redaction-geneve-infos\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/author\\\/redaction-geneve-infos\\\/#author\"},\"datePublished\":\"2026-11-12T07:08:00+01:00\",\"dateModified\":\"2026-11-12T23:10:29+01:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/\",\"name\":\"Gen\\u00e8ve Infos\",\"alternateName\":\"GeneveInfos\",\"description\":\"L\\u2019actu genevoise et romande\",\"inLanguage\":\"en-GB\",\"publisher\":{\"@id\":\"https:\\\/\\\/geneveinfos.ch\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Neurosterix: Geneva biotech raises 105 million dollars","description":"Neurosterix, a Geneva biotech spun out of Addex, raises 105 million dollars in Series B for the phase 2 trial of NTX-253 in schizophrenia.","canonical_url":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"msvalidate.01":"F6FB81358B9B97D1D2B21C8A22A9AB69","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/geneveinfos.ch\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/geneveinfos.ch\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/geneveinfos.ch\/en\/category\/pharma-biotech\/#listItem","name":"Pharma &amp; biotech"}},{"@type":"ListItem","@id":"https:\/\/geneveinfos.ch\/en\/category\/pharma-biotech\/#listItem","position":2,"name":"Pharma &amp; biotech","item":"https:\/\/geneveinfos.ch\/en\/category\/pharma-biotech\/","nextItem":{"@type":"ListItem","@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#listItem","name":"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars"},"previousItem":{"@type":"ListItem","@id":"https:\/\/geneveinfos.ch\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#listItem","position":3,"name":"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars","previousItem":{"@type":"ListItem","@id":"https:\/\/geneveinfos.ch\/en\/category\/pharma-biotech\/#listItem","name":"Pharma &amp; biotech"}}]},{"@type":"NewsArticle","@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#newsarticle","name":"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars","headline":"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars","author":{"@id":"https:\/\/geneveinfos.ch\/en\/author\/redaction-geneve-infos\/#author"},"publisher":{"@id":"https:\/\/geneveinfos.ch\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/geneveinfos.ch\/wp-content\/uploads\/2026\/11\/logo-geneveinfos-fr.png","@id":"https:\/\/geneveinfos.ch\/en\/#articleImage","width":920,"height":958,"caption":"Gen\u00e8ve Infos \u2013 logo"},"datePublished":"2026-11-12T07:08:00+01:00","dateModified":"2026-11-12T23:10:29+01:00","inLanguage":"en-GB","mainEntityOfPage":{"@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#webpage"},"isPartOf":{"@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#webpage"},"articleSection":"Actus, Pharma &amp; biotech, Fiche bilingue, Gen\u00e8ve","dateline":"Published on November 12, 2026."},{"@type":"Organization","@id":"https:\/\/geneveinfos.ch\/en\/#organization","name":"Gen\u00e8ve Infos","description":"M\u00e9dia \u00e9conomique de Gen\u00e8ve et de toute la Suisse romande. Actus, articles et agenda, de Gen\u00e8ve au Jura.","url":"https:\/\/geneveinfos.ch\/en\/","logo":{"@type":"ImageObject","url":"https:\/\/geneveinfos.ch\/wp-content\/uploads\/2026\/11\/logo-geneveinfos-fr.png","@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#organizationLogo","width":920,"height":958,"caption":"Gen\u00e8ve Infos \u2013 logo"},"image":{"@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61576016541234","https:\/\/www.instagram.com\/geneveinfos.ch\/","https:\/\/www.linkedin.com\/company\/geneveinfos-ch"]},{"@type":"Person","@id":"https:\/\/geneveinfos.ch\/en\/author\/redaction-geneve-infos\/#author","url":"https:\/\/geneveinfos.ch\/en\/author\/redaction-geneve-infos\/","name":"Morgane Ravouna","image":{"@type":"ImageObject","@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/4a611ac9406717aef02499144d0e12a8f5e1327b66a2e6023de2c094c4937e1d?s=96&d=mm&r=g","width":96,"height":96,"caption":"Morgane Ravouna"}},{"@type":"WebPage","@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#webpage","url":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/","name":"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars","description":"Neurosterix, biotech genevoise issue d\u2019Addex, l\u00e8ve 105 millions de dollars en s\u00e9rie B pour l\u2019essai de phase 2 du NTX-253 contre la schizophr\u00e9nie.","inLanguage":"en-GB","isPartOf":{"@id":"https:\/\/geneveinfos.ch\/en\/#website"},"breadcrumb":{"@id":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/#breadcrumblist"},"author":{"@id":"https:\/\/geneveinfos.ch\/en\/author\/redaction-geneve-infos\/#author"},"creator":{"@id":"https:\/\/geneveinfos.ch\/en\/author\/redaction-geneve-infos\/#author"},"datePublished":"2026-11-12T07:08:00+01:00","dateModified":"2026-11-12T23:10:29+01:00"},{"@type":"WebSite","@id":"https:\/\/geneveinfos.ch\/en\/#website","url":"https:\/\/geneveinfos.ch\/en\/","name":"Gen\u00e8ve Infos","alternateName":"GeneveInfos","description":"L\u2019actu genevoise et romande","inLanguage":"en-GB","publisher":{"@id":"https:\/\/geneveinfos.ch\/en\/#organization"}}]},"og:locale":"en_GB","og:site_name":"Gen\u00e8ve Infos - L\u2019actu genevoise et romande","og:type":"article","og:title":"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars","og:description":"Neurosterix, biotech genevoise issue d\u2019Addex, l\u00e8ve 105 millions de dollars en s\u00e9rie B pour l\u2019essai de phase 2 du NTX-253 contre la schizophr\u00e9nie.","og:url":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/","og:image":"https:\/\/geneveinfos.ch\/wp-content\/uploads\/2026\/11\/geneveinfos-partage-2026-en.jpg","og:image:secure_url":"https:\/\/geneveinfos.ch\/wp-content\/uploads\/2026\/11\/geneveinfos-partage-2026-en.jpg","og:image:width":1200,"og:image:height":630,"article:published_time":"2026-11-12T06:08:00+00:00","article:modified_time":"2026-11-12T22:10:29+00:00","article:publisher":"https:\/\/www.facebook.com\/profile.php?id=61576016541234","twitter:card":"summary_large_image","twitter:title":"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars","twitter:description":"Neurosterix, biotech genevoise issue d\u2019Addex, l\u00e8ve 105 millions de dollars en s\u00e9rie B pour l\u2019essai de phase 2 du NTX-253 contre la schizophr\u00e9nie.","twitter:image":"https:\/\/geneveinfos.ch\/wp-content\/uploads\/2026\/11\/geneveinfos-partage-2026-en.jpg"},"aioseo_meta_data":{"post_id":"334951","title":null,"description":"Neurosterix, a Geneva biotech spun out of Addex, raises 105 million dollars in Series B for the phase 2 trial of NTX-253 in schizophrenia.","keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2026-11-12 22:10:31","updated":"2026-11-12 22:23:29","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/geneveinfos.ch\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/geneveinfos.ch\/en\/category\/pharma-biotech\/\" title=\"Pharma &amp; biotech\">Pharma &amp; biotech<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tNeurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/geneveinfos.ch\/en\/"},{"label":"Pharma &amp; biotech","link":"https:\/\/geneveinfos.ch\/en\/category\/pharma-biotech\/"},{"label":"Neurosterix : la biotech genevoise l\u00e8ve 105 millions de dollars","link":"https:\/\/geneveinfos.ch\/en\/2026\/11\/12\/neurosterix-la-biotech-genevoise-leve-105-millions-de-dollars\/"}],"_links":{"self":[{"href":"https:\/\/geneveinfos.ch\/en\/wp-json\/wp\/v2\/posts\/334951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/geneveinfos.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/geneveinfos.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/geneveinfos.ch\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/geneveinfos.ch\/en\/wp-json\/wp\/v2\/comments?post=334951"}],"version-history":[{"count":0,"href":"https:\/\/geneveinfos.ch\/en\/wp-json\/wp\/v2\/posts\/334951\/revisions"}],"wp:attachment":[{"href":"https:\/\/geneveinfos.ch\/en\/wp-json\/wp\/v2\/media?parent=334951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/geneveinfos.ch\/en\/wp-json\/wp\/v2\/categories?post=334951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/geneveinfos.ch\/en\/wp-json\/wp\/v2\/tags?post=334951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}